Corcept Securities Class Action Reminder for Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CORT?
Source: Globenewswire
- Lawsuit Deadline: Investors must file lead plaintiff applications for the Corcept securities class action by April 21, 2026, concerning trades made between October 31, 2024, and December 30, 2025, or risk losing their right to claim.
- Stock Price Plunge: On December 31, 2025, Corcept's stock price plummeted by $35.40, a 50.4% drop from $70.20 to $34.80, following the FDA's rejection of its new drug application, severely impacting investor confidence and the company's market capitalization.
- Legal Allegations Context: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors regarding the likelihood of FDA approval for a key product candidate.
- Law Firm's Role: Kahn Swick & Foti, LLC, a leading securities litigation firm, is reminding investors to pay attention to this case and offers legal consultation services to help investors understand their rights and potential compensation for economic losses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 40.850
Low
50.00
Averages
91.00
High
121.00
Current: 40.850
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept Securities Class Action Reminder for Investors
- Lawsuit Deadline: Investors must file lead plaintiff applications for the Corcept securities class action by April 21, 2026, concerning trades made between October 31, 2024, and December 30, 2025, or risk losing their right to claim.
- Stock Price Plunge: On December 31, 2025, Corcept's stock price plummeted by $35.40, a 50.4% drop from $70.20 to $34.80, following the FDA's rejection of its new drug application, severely impacting investor confidence and the company's market capitalization.
- Legal Allegations Context: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors regarding the likelihood of FDA approval for a key product candidate.
- Law Firm's Role: Kahn Swick & Foti, LLC, a leading securities litigation firm, is reminding investors to pay attention to this case and offers legal consultation services to help investors understand their rights and potential compensation for economic losses.
See More
CORT Investors Encouraged to Act on Losses
- Lawsuit Notification: Hagens Berman reminds investors in Corcept Therapeutics (NASDAQ:CORT) that the deadline to apply for Lead Plaintiff in the securities class action for losses incurred between October 31, 2024, and December 30, 2025, is April 21, 2026, urging timely contact to protect their rights.
- Lawsuit Background: The lawsuit, filed by the Allegheny County Employees' Retirement System, alleges that Corcept made materially false and misleading statements regarding its lead drug candidate, relacorilant, failing to disclose critical FDA feedback during the Class Period, resulting in investor losses.
- Information Discrepancy: Reed Kathrein, a partner at Hagens Berman, highlighted a significant 'information gap' between what Corcept disclosed publicly and what the FDA reportedly communicated privately, which could mislead investors and exacerbate market uncertainty.
- Whistleblower Program: Hagens Berman encourages whistleblowers with non-public information about Corcept to participate in the investigation, as the SEC Whistleblower program offers rewards of up to 30% of any successful recovery, incentivizing investor and insider engagement.
See More
Class Action Lawsuits Filed Against Kyndryl and Others
- Kyndryl Lawsuit Overview: Kyndryl Holdings, Inc. faces a class action from August 1, 2024, to February 9, 2026, due to materially false financial statements and inadequate internal controls, which severely undermines investor confidence and is expected to negatively impact stock performance.
- PayPal Legal Issues: PayPal Holdings, Inc. is involved in a class action from February 8, 2024, to February 2, 2026, for failing to effectively execute branded checkout initiatives and overstating its business execution capabilities, leading to diminished investor confidence in its market competitiveness, potentially affecting future performance.
- NuScale Risk Disclosure: NuScale Power Corporation is facing a class action from May 13, 2025, to November 6, 2025, for failing to disclose significant risks associated with its nuclear projects, which damages investor confidence in its commercialization strategy and may hinder its financing capabilities.
- Corcept FDA Concerns: Corcept Therapeutics Incorporated is involved in a class action from October 31, 2024, to January 30, 2026, due to undisclosed FDA concerns regarding the effectiveness assessment of its drug, leading to investor doubts about future regulatory approval prospects, potentially impacting its stock price.
See More
Corcept Therapeutics Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Corcept (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to represent other investors in the class action lawsuit.
- No Out-of-Pocket Fees: Investors participating in the class action may receive compensation without any upfront costs through a contingency fee arrangement, which lowers the financial barrier for more investors to join the lawsuit.
- FDA Approval Risks: The lawsuit claims that throughout the class period, Corcept misrepresented the strength of clinical trials supporting its drug relacorilant for hypercortisolism treatment, while the FDA had raised concerns about the adequacy of clinical evidence, exposing investors to significant risks.
- Choosing Counsel: Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record, noting that many firms issuing notices lack the necessary experience in handling securities class actions, urging investors to be cautious in their choices to ensure their rights are effectively protected.
See More
UnitedHealthcare Shares Climb 9%, Humana Up 11% in After-Hours Trading After CMS Medicare Announcement
Healthcare Shares Rise: Shares of UnitedHealth Care increased by 9% following the announcement from CMS regarding Medicare.
Humana Gains: Humana's shares saw an 11% rise in after-hours trading, reflecting positive market reactions to the same CMS announcement.
See More
Corcept Therapeutics Faces Class Action for Securities Fraud
- Lawsuit Reminder: The Schall Law Firm is reminding investors of a class action lawsuit against Corcept Therapeutics (NASDAQ:CORT) for violations of securities laws during the period from October 31, 2024, to December 30, 2025, with a deadline to contact the firm by April 21, 2026, to participate.
- False Statements: The complaint alleges that Corcept made false and misleading statements regarding its product candidate, relacorilant, claiming it was 'approaching approval' while knowing that the FDA deemed its clinical data inadequate for approval, resulting in investor losses.
- Loss Recovery: Investors suffered damages when the truth about Corcept was revealed, and the Schall Law Firm specializes in securities class action lawsuits, aiming to assist affected shareholders in recovering their losses, highlighting the importance of legal recourse.
- Legal Process: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who take no action will remain absent class members, urging investors to act promptly to protect their rights.
See More
Corcept Securities Class Action Reminder for Investors
- Lawsuit Deadline: Investors must file lead plaintiff applications for the Corcept securities class action by April 21, 2026, concerning trades made between October 31, 2024, and December 30, 2025, or risk losing their right to claim.
- Stock Price Plunge: On December 31, 2025, Corcept's stock price plummeted by $35.40, a 50.4% drop from $70.20 to $34.80, following the FDA's rejection of its new drug application, severely impacting investor confidence and the company's market capitalization.
- Legal Allegations Context: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors regarding the likelihood of FDA approval for a key product candidate.
- Law Firm's Role: Kahn Swick & Foti, LLC, a leading securities litigation firm, is reminding investors to pay attention to this case and offers legal consultation services to help investors understand their rights and potential compensation for economic losses.
See More
CORT Investors Encouraged to Act on Losses
- Lawsuit Notification: Hagens Berman reminds investors in Corcept Therapeutics (NASDAQ:CORT) that the deadline to apply for Lead Plaintiff in the securities class action for losses incurred between October 31, 2024, and December 30, 2025, is April 21, 2026, urging timely contact to protect their rights.
- Lawsuit Background: The lawsuit, filed by the Allegheny County Employees' Retirement System, alleges that Corcept made materially false and misleading statements regarding its lead drug candidate, relacorilant, failing to disclose critical FDA feedback during the Class Period, resulting in investor losses.
- Information Discrepancy: Reed Kathrein, a partner at Hagens Berman, highlighted a significant 'information gap' between what Corcept disclosed publicly and what the FDA reportedly communicated privately, which could mislead investors and exacerbate market uncertainty.
- Whistleblower Program: Hagens Berman encourages whistleblowers with non-public information about Corcept to participate in the investigation, as the SEC Whistleblower program offers rewards of up to 30% of any successful recovery, incentivizing investor and insider engagement.
See More
Class Action Lawsuits Filed Against Kyndryl and Others
- Kyndryl Lawsuit Overview: Kyndryl Holdings, Inc. faces a class action from August 1, 2024, to February 9, 2026, due to materially false financial statements and inadequate internal controls, which severely undermines investor confidence and is expected to negatively impact stock performance.
- PayPal Legal Issues: PayPal Holdings, Inc. is involved in a class action from February 8, 2024, to February 2, 2026, for failing to effectively execute branded checkout initiatives and overstating its business execution capabilities, leading to diminished investor confidence in its market competitiveness, potentially affecting future performance.
- NuScale Risk Disclosure: NuScale Power Corporation is facing a class action from May 13, 2025, to November 6, 2025, for failing to disclose significant risks associated with its nuclear projects, which damages investor confidence in its commercialization strategy and may hinder its financing capabilities.
- Corcept FDA Concerns: Corcept Therapeutics Incorporated is involved in a class action from October 31, 2024, to January 30, 2026, due to undisclosed FDA concerns regarding the effectiveness assessment of its drug, leading to investor doubts about future regulatory approval prospects, potentially impacting its stock price.
See More
Corcept Therapeutics Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Corcept (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to represent other investors in the class action lawsuit.
- No Out-of-Pocket Fees: Investors participating in the class action may receive compensation without any upfront costs through a contingency fee arrangement, which lowers the financial barrier for more investors to join the lawsuit.
- FDA Approval Risks: The lawsuit claims that throughout the class period, Corcept misrepresented the strength of clinical trials supporting its drug relacorilant for hypercortisolism treatment, while the FDA had raised concerns about the adequacy of clinical evidence, exposing investors to significant risks.
- Choosing Counsel: Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record, noting that many firms issuing notices lack the necessary experience in handling securities class actions, urging investors to be cautious in their choices to ensure their rights are effectively protected.
See More
UnitedHealthcare Shares Climb 9%, Humana Up 11% in After-Hours Trading After CMS Medicare Announcement
Healthcare Shares Rise: Shares of UnitedHealth Care increased by 9% following the announcement from CMS regarding Medicare.
Humana Gains: Humana's shares saw an 11% rise in after-hours trading, reflecting positive market reactions to the same CMS announcement.
See More
Corcept Therapeutics Faces Class Action for Securities Fraud
- Lawsuit Reminder: The Schall Law Firm is reminding investors of a class action lawsuit against Corcept Therapeutics (NASDAQ:CORT) for violations of securities laws during the period from October 31, 2024, to December 30, 2025, with a deadline to contact the firm by April 21, 2026, to participate.
- False Statements: The complaint alleges that Corcept made false and misleading statements regarding its product candidate, relacorilant, claiming it was 'approaching approval' while knowing that the FDA deemed its clinical data inadequate for approval, resulting in investor losses.
- Loss Recovery: Investors suffered damages when the truth about Corcept was revealed, and the Schall Law Firm specializes in securities class action lawsuits, aiming to assist affected shareholders in recovering their losses, highlighting the importance of legal recourse.
- Legal Process: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who take no action will remain absent class members, urging investors to act promptly to protect their rights.
See More
